Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct 22;11(1):20938.
doi: 10.1038/s41598-021-00418-z.

Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system

Hojin Oh  1 , Hai Duc Nguyen  1 , In Mo Yoon  2 , Byung-Ryong Ahn  3 , Min-Sun Kim  4
Affiliations
Meta-Analysis

Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system

Hojin Oh et al. Sci Rep. .

Abstract

Gemigliptin is one of the latest dipeptidyl peptidase-4 inhibitors developed by LG Life Sciences. Since the early 2000s, several randomized controlled trials (RCTs) of gemigliptin have been conducted. However, no study has directly compared its antidiabetic effects through a systematic review and meta-analysis. Therefore, in this study, we performed a systematic review and meta-analysis on RCTs. In particular, a subsequent meta-analysis was performed using Bayesian inference, and an updated quality management system model was integrated throughout our study. The mean differences and 95% confidence intervals for glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), homeostatic model assessment beta cell function (HOMA-β), and low-density lipoprotein (LDL) were evaluated for the efficacy outcomes of gemigliptin as compared to those of placebo and other oral antidiabetic drugs (OADs). In conclusion, we found that gemigliptin was superior to placebo and comparable to other OADs in terms of the effect on HbA1c, FPG, HOMA-β, and LDL. Further, gemigliptin was more effective than other OADs in HbA1c and HOMA-β in Bayesian inference analysis and statistically significant to other OADs in HbA1c and HOMA-β in sensitivity analysis excluding metformin. However, to confirm the results, more studies need to be analysed and the minimum clinically important difference must be applied.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study procedure using the quality management system.
Figure 2
Figure 2
Flow chart of the studies selected and included in the meta-analysis.
Figure 3
Figure 3
Quality assessment of the risk of bias of the eleven selected RCTs.
Figure 4
Figure 4
Forest plot of RCTs for the effect of gemigliptin on HbA1c.
Figure 5
Figure 5
Forrest plot of RCTs for the effect of gemigliptin on FPG.
Figure 6
Figure 6
Forest plot of RCTs for the effect of gemigliptin on HOMA-β.
Figure 7
Figure 7
Forest plot of RCTs for the effect of gemigliptin on LDL.
Figure 8
Figure 8
Sensitivity analysis of the studies examined for HbA1c, FPG, HOMA-β, and LDL.
Figure 9
Figure 9
Funnel plots of the MDs versus the standard error of the MDs for HbA1c, FPG, HOMA-β, and LDL.
See this image and copyright information in PMC

References

    1. Lim KS, et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study. Clin. Ther. 2008;30:1817–1830. doi: 10.1016/j.clinthera.2008.10.013. - DOI - PubMed
    1. Kim SH, Lee SH, Yim HJ. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: First new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch. Pharm. Res. 2013;36:1185–1188. doi: 10.1007/s12272-013-0171-x. - DOI - PubMed
    1. IQVIA Data. Sales trend of new domestic drugs in 2019. Kmedinfo Web. http://m.kmedinfo.co.kr/news/articleView.html?idxno=59857 (2019).
    1. Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur. J. Pharmacol. 2016;788:54–64. doi: 10.1016/j.ejphar.2016.06.016. - DOI - PubMed
    1. Lim KS, et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br. J. Clin. Pharmacol. 2009;68:883–890. doi: 10.1111/j.1365-2125.2009.03376.x. - DOI - PMC - PubMed

Publication types